Sensei Biotherapeutics, Inc. (NASDAQ:FTH) Stock Has Consensus Target Price of $56.25 According to Analysts

by · The Cerbat Gem

Sensei Biotherapeutics, Inc. (NASDAQ:FTH – Get Free Report) has been given a consensus rating of “Moderate Buy” by the fifteen ratings firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, eleven have given a buy rating and two have issued a strong buy rating on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $56.25.

Several research firms have weighed in on FTH. Cantor Fitzgerald reissued an “overweight” rating on shares of Sensei Biotherapeutics in a research note on Thursday, June 4th. Loop Capital set a $50.00 price objective on Sensei Biotherapeutics in a research note on Thursday, May 28th. Needham & Company LLC initiated coverage on Sensei Biotherapeutics in a report on Friday, August 21st. They issued a “buy” rating and a $56.00 price objective on the stock. Raymond James Financial assumed coverage on Sensei Biotherapeutics in a research note on Friday, July 31st. They issued an “outperform” rating and a $56.00 target price for the company. Finally, HC Wainwright restated a “buy” rating and set a $60.00 target price on shares of Sensei Biotherapeutics in a report on Tuesday, August 11th.

Check Out Our Latest Analysis on Sensei Biotherapeutics

Sensei Biotherapeutics Price Performance

FTH stock opened at $29.05 on Friday. The stock has a market capitalization of $750.65 million, a P/E ratio of -0.21 and a beta of -0.28. Sensei Biotherapeutics has a one year low of $7.45 and a one year high of $42.14. The business’s 50 day simple moving average is $32.03.

Sensei Biotherapeutics (NASDAQ:FTH – Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($2.84) earnings per share for the quarter, topping analysts’ consensus estimates of ($5.04) by $2.20. As a group, equities analysts forecast that Sensei Biotherapeutics will post -13.69 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Brian C. Stephenson acquired 5,000 shares of the stock in a transaction on Wednesday, July 1st. The stock was purchased at an average price of $23.50 per share, for a total transaction of $117,500.00. Following the completion of the transaction, the chief financial officer owned 46,688 shares of the company’s stock, valued at $1,097,168. This trade represents a 11.99% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders purchased a total of 13,634 shares of company stock valued at $326,118 in the last ninety days. Insiders own 7.00% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in FTH. Citadel Advisors LLC bought a new stake in Sensei Biotherapeutics during the 2nd quarter valued at $307,000. Renaissance Technologies LLC grew its holdings in Sensei Biotherapeutics by 178.2% in the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock worth $1,010,000 after acquiring an additional 20,525 shares during the last quarter. Bank of America Corp DE grew its holdings in Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after acquiring an additional 32,719 shares during the last quarter. Stempoint Capital LP purchased a new position in shares of Sensei Biotherapeutics in the first quarter valued at about $4,188,000. Finally, Alyeska Investment Group L.P. purchased a new position in shares of Sensei Biotherapeutics in the second quarter valued at about $3,610,000. Institutional investors own 10.50% of the company’s stock.

About Sensei Biotherapeutics

(Get Free Report)

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for the treatment of cancer. The company’s research is centered on activating and directing the immune system to recognize and attack tumor cells.

Sensei’s technology platform is designed to generate Immune Modulating Antibodies, or IMAs, which are intended to stimulate anti-tumor immune responses by targeting mechanisms involved in immune regulation. Its development programs have included antibody-based therapies evaluated for solid tumors, including programs studied in combination with established checkpoint inhibitors.

The company was founded in 2018 and is based in Cambridge, Massachusetts.

Featured Stories